Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
暂无分享,去创建一个
M. Taniwaki | Y. Ohashi | Y. Matsuno | S. Nawano | M. Ogura | S. Mori | A. Utsunomiya | K. Tobinai | Y. Morishima | Takashi Watanabe | T. Hotta | T. Terauchi | T. Seriu | H. Minami | M. Matsusako | Y. Ogawa | Shigeo Nakamura | M. Hayashi | K. Ishizawa | S. Nakamura | S. Nakamura
[1] P. Solal-Céligny. Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.
[2] M. Czuczman,et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] 渡邉 隆. What's going on 造血器腫瘍 Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. J Clin Oncol. 2004;22:4659-64. PMID:15483 , 2005 .
[4] M. Czuczman,et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Hiddemann,et al. The role of fludarabine in the treatment of follicular and mantle cell lymphoma , 2004, Cancer.
[6] M. Samuel,et al. Fludarabine in Comparison to Alkylator-based Regimen as Induction Therapy for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis , 2004, Leukemia & lymphoma.
[7] C. Sawka,et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M Taniwaki,et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] F. Bosch,et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Gobbi,et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] B. Freidlin,et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] T. Lister,et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] B. Coiffier,et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] L. Gordon,et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Bosq,et al. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Falkson. Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma. , 1996, American journal of clinical oncology.
[20] P. Mclaughlin,et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Horning. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.
[22] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[23] R. Fanin,et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] B. Nathwani,et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] W. Velasquez,et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Oken,et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] T. Lister,et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. , 1991, British Journal of Cancer.
[28] J. V. van Dongen,et al. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. , 1990, The American journal of pathology.
[29] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.